title: Comparison of efavirenz and protease inhibitor based combination antiretroviral therapy regimens in treatment-naïve people living with HIV with baseline resistance.
abstract: A retrospective cohort analysis comparing the efficacy of boosted protease inhibitor-based and efavirenz-based combination antiretroviral therapy in treatment-naïve people living with HIV with baseline resistance found that efavirenz-based treatment led to a shorter mean time to undetectable viral load. A higher proportion of patients with nonnucleoside reverse transcriptase inhibitor related baseline resistance mutations in the efavirenz-treatment group achieved an undetectable viral load at both 6 and 12 months post-treatment initiation, compared with the boosted protease-inhibitor-treatment group.Supplementary content: http://links.lww.com/QAD/A930.
authors.affiliation: aImperial College London, South Kensington CampusbChelsea and Westminster Hospital NHS Foundation TrustcBarts Healthcare NHS Trust, London, UK.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Lim
authors.forename: Katie
authors.initials: K
authors.lastname: McFaul
authors.forename: Samuel
authors.initials: S
authors.lastname: Kabagambe
authors.forename: Sonali
authors.initials: S
authors.lastname: Sonecha
authors.forename: Rachael
authors.initials: R
authors.lastname: Jones
authors.forename: David
authors.initials: D
authors.lastname: Asboe
authors.forename: Anton
authors.initials: A
authors.lastname: Pozniak
authors.forename: Nneka
authors.initials: N
authors.lastname: Nwokolo
authors.forename: Marta
authors.initials: M
authors.lastname: Boffito
mesh_terms: D000480:Alkynes; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D048588:Benzoxazines / Q000627:therapeutic use*; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000072230:Sustained Virologic Response; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000480:Alkynes; D044966:Anti-Retroviral Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz